Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Dyskinesia Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Dyskinesia Overview | 13 | 1 |
| Pipeline Products for Dyskinesia Comparative Analysis | 14 | 1 |
| Dyskinesia Therapeutics under Development by Companies | 15 | 3 |
| Dyskinesia Therapeutics under Investigation by Universities/Institutes | 18 | 1 |
| Dyskinesia Pipeline Products Glance | 19 | 3 |
| Late Stage Products | 19 | 1 |
| Clinical Stage Products | 20 | 1 |
| Early Stage Products | 21 | 1 |
| Dyskinesia Products under Development by Companies | 22 | 3 |
| Dyskinesia Products under Investigation by Universities/Institutes | 25 | 1 |
| Dyskinesia Companies Involved in Therapeutics Development | 26 | 28 |
| Adamas Pharmaceuticals, Inc. | 26 | 1 |
| Addex Therapeutics Ltd | 27 | 1 |
| Advicenne | 28 | 1 |
| Astraea Therapeutics, LLC | 29 | 1 |
| Bionomics Limited | 30 | 1 |
| Catalyst Biosciences, Inc. | 31 | 1 |
| Catalyst Pharmaceuticals, Inc. | 32 | 1 |
| Clevexel Pharma SAS | 33 | 1 |
| Contera Pharma ApS | 34 | 1 |
| EpiVax, Inc. | 35 | 1 |
| Heptares Therapeutics Limited | 36 | 1 |
| Hua Medicine (Shanghai) Ltd. | 37 | 1 |
| Integrative Research Laboratories Sweden AB | 38 | 1 |
| Ipsen S.A. | 39 | 1 |
| Merz Pharma GmbH &Co. KgaA | 40 | 1 |
| MitoDys Therapeutics Limited | 41 | 1 |
| Neurim Pharmaceuticals Ltd | 42 | 1 |
| Neurocrine Biosciences, Inc. | 43 | 1 |
| Neurolixis Inc. | 44 | 1 |
| Osmotica Pharmaceutical Corp. | 45 | 1 |
| Otsuka Holdings Co., Ltd. | 46 | 1 |
| Phenomenome Discoveries, Inc. | 47 | 1 |
| Revance Therapeutics, Inc. | 48 | 1 |
| Sage Therapeutics, Inc. | 49 | 1 |
| SciFluor Life Sciences, LLC | 50 | 1 |
| SOM Innovation Biotech SL | 51 | 1 |
| Synchroneuron Inc. | 52 | 1 |
| Teva Pharmaceutical Industries Ltd. | 53 | 1 |
| Dyskinesia Therapeutics Assessment | 54 | 12 |
| Assessment by Monotherapy Products | 54 | 1 |
| Assessment by Combination Products | 55 | 1 |
| Assessment by Target | 56 | 3 |
| Assessment by Mechanism of Action | 59 | 3 |
| Assessment by Route of Administration | 62 | 2 |
| Assessment by Molecule Type | 64 | 2 |
| Drug Profiles | 66 | 84 |
| (dextromethorphan + quinidine sulfate) Drug Profile | 66 | 5 |
| A2M-13677 Drug Profile | 71 | 1 |
| abobotulinumtoxin A Drug Profile | 72 | 4 |
| acamprosate calcium SR Drug Profile | 76 | 2 |
| amantadine hydrochloride ER Drug Profile | 78 | 6 |
| amantadine hydrochloride ER Drug Profile | 84 | 1 |
| AT-127 Drug Profile | 85 | 1 |
| AT-326 Drug Profile | 86 | 1 |
| AT-403 Drug Profile | 87 | 1 |
| befiradol Drug Profile | 88 | 2 |
| CPP-115 Drug Profile | 90 | 4 |
| CVXL-0107 Drug Profile | 94 | 1 |
| deutetrabenazine ER Drug Profile | 95 | 4 |
| dipraglurant ER Drug Profile | 99 | 1 |
| dipraglurant IR Drug Profile | 100 | 4 |
| Drug for Dyskinesia Drug Profile | 104 | 1 |
| HTL-14242 Drug Profile | 105 | 1 |
| incobotulinumtoxin A Drug Profile | 106 | 3 |
| IRL-790 Drug Profile | 109 | 1 |
| JM-010 Drug Profile | 110 | 2 |
| MLR-1019 Drug Profile | 112 | 1 |
| NBI-640756 Drug Profile | 113 | 1 |
| Neu-120 Drug Profile | 114 | 1 |
| Neu-240 Drug Profile | 115 | 1 |
| onabotulinumtoxinA Drug Profile | 116 | 1 |
| PEUN-3 Drug Profile | 117 | 1 |
| PPI-1011 Drug Profile | 118 | 1 |
| remeglurant Drug Profile | 119 | 1 |
| RT-002 Drug Profile | 120 | 2 |
| SAGE-217 Drug Profile | 122 | 2 |
| sepranolone Drug Profile | 124 | 7 |
| SK-609 Drug Profile | 131 | 1 |
| Small Molecule for Dyskinesia Drug Profile | 132 | 1 |
| Small Molecule for Dyskinesia and Hyperkinesia Drug Profile | 133 | 1 |
| Small Molecules for Neurodegenerative Disease Drug Profile | 134 | 1 |
| Small Molecules for Tardive Dyskinesia Drug Profile | 135 | 1 |
| Small Molecules to Antagonize GPCR for Central Nervous System Diseases Drug Profile | 136 | 1 |
| Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia Drug Profile | 137 | 1 |
| Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders Drug Profile | 138 | 1 |
| Small Molecules to Antagonize mGluR5 for Dyskinesia Drug Profile | 139 | 1 |
| Small Molecules to Target Ion Channels for CNS Disorders Drug Profile | 140 | 1 |
| SOM-3355 Drug Profile | 141 | 1 |
| TC-8831 Drug Profile | 142 | 1 |
| tetrabenazine Drug Profile | 143 | 1 |
| valbenazine tosylate Drug Profile | 144 | 6 |
| Dyskinesia Dormant Projects | 150 | 3 |
| Dyskinesia Discontinued Products | 153 | 1 |
| Dyskinesia Product Development Milestones | 154 | 15 |
| Featured News &Press Releases | 154 | 1 |
| Aug 31, 2016: Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA for VMAT2 Inhibitor Valbenazine | 154 | 1 |
| Aug 29, 2016: Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia | 154 | 1 |
| Jun 22, 2016: Adamas Announces Additional ADS-5102 Data for the Treatment of Levodopa-induced Dyskinesia at the International Congress of Parkinsons Disease and Movement Disorders | 154 | 2 |
| Jun 20, 2016: Teva to Present Data Highlighting SD-809 at 20th International Congress of Parkinson's Disease and Movement Disorders | 156 | 1 |
| Jun 20, 2016: Teva to Present Data Highlighting SD-809 at 20th International Congress of Parkinson's Disease and Movement Disorders | 157 | 1 |
| Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society | 157 | 2 |
| May 31, 2016: Teva Receives Complete Response Letter for NDA for SD-809 for the Treatment of Chorea Associated with Huntington Disease | 159 | 1 |
| May 16, 2016: Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia at the 20th International Congress of Parkinsons and Movement Disorders | 159 | 1 |
| May 06, 2016: Neurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data to be Presented at the American Psychiatric Association 2016 Annual Meeting in Atlanta | 160 | 1 |
| Apr 28, 2016: Adamas Announces Positive Top-line Results from its Phase 3 EASE LID 3 Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease | 160 | 2 |
| Apr 19, 2016: Adamas Presents Positive Findings From the Phase 3 EASE LID Clinical Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia Associated with Parkinson's Disease at the American Academy of Neurology Annual Meeting | 162 | 2 |
| Apr 18, 2016: Teva Presents New Data for SD-809 in Huntington Disease at 68th American Academy of Neurology Annual Meeting in Vancouver, B.C. | 164 | 1 |
| Apr 17, 2016: Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting | 165 | 2 |
| Apr 14, 2016: Adamas Announces Data Update at the 68th American Academy of Neurology Annual Meeting | 167 | 1 |
| Apr 12, 2016: Teva to Present Data on SD-809 (deutetrabenazine) at 68th AAN Annual Meeting | 168 | 1 |
| Appendix | 169 | 2 |
| Methodology | 169 | 1 |
| Coverage | 169 | 1 |
| Secondary Research | 169 | 1 |
| Primary Research | 169 | 1 |
| Expert Panel Validation | 169 | 1 |
| Contact Us | 169 | 1 |
| Disclaimer | 170 | 1 |
